About Bioline  All Journals  Testimonials  Membership  News  Donations

Indian Journal of Cancer
Medknow Publications on behalf of Indian Cancer Society
ISSN: 0019-509X
EISSN: 1998-4774
Vol. 39, No. 4, 2002, pp. 127-134
Bioline Code: cn02009
Full paper language: English
Document type: Research Article
Document available free of charge

Indian Journal of Cancer, Vol. 39, No. 4, 2002, pp. 127-134

 en Hypofractionated Radiotherapy in Carcinoma Cervix IIIB Tata Memorial Hospital Experience
Mary A. Muckaden, Ashwini N. Budrukkar, Hemant B. Tongaonkar, Ketayun A. Dinshaw


PURPOSE OF THE STUDY: To analyze the role of hypofractionated radiotherapy in advanced carcinoma of cervix.

BASIC PROCEDURE: Medical records of 62 women with advanced carcinoma cervix III3 treated during 1994-1996 were reviewed. Patients were treated with standard pelvic portals to a total dose of 39Gy in 13 fractions over 17 days followed by intracavitary brachytherapy. Forty-eight patients completed the planned treatment and were considered suitable for analysis of late reactions and survival.

MAIN FINDINGS: The 5-year disease free survival was 59% and the overall survival was 50% at the mean follow up of 40 months.

Twenty-one (44%) patients developed acute gastrointestinal toxicity of which 5 patients had grade III and one patient had grade IV reaction. Ten patients (21%) developed acute genitourinary complications, 13 patients (27%) had late rectal reactions and 10 patients (20%) had late bladder complications. Three patients had grade I, five had grade II and five had grade III late rectal toxicity.

CONCLUSION: Survival in patients treated hypofractionated radiotherapy appears comparable to that of standard fractionation. The acute gastrointestinal and skin reactions were mainly grade I or grade II. Hypofractionated radiotherapy can certainly be considered in a select group of patients where the local disease is extensive and is unsuitable for conventional treatment.

Hypofractionation, Cancer cervix, Radiation Therapy

© Copyright 2002 - Indian Journal of Cancer.
Alternative site location:

Home Faq Resources Email Bioline
© Bioline International, 1989 - 2022, Site last up-dated on 19-Jan-2022.
Site created and maintained by the Reference Center on Environmental Information, CRIA, Brazil
System hosted by the Internet Data Center of Rede Nacional de Ensino e Pesquisa, RNP, Brazil